Developer docs
API playgroundTry for free, no card

Search company profiles

Arrowsmith

Full company profile

uuid02ihalo

Namestring
Arrowsmith
Legal namestring
Arrowsmith Inc.
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Arrowsmith Inc. is a Japan-based, privately held biotechnology company founded in 2025 and headquartered in Ibaraki. Its stated mission is to address antimicrobial resistance (AMR), positioning the company in the global effort to develop countermeasures against drug-resistant infections. The company is in an early operational stage, with a headcount reported at 1-10 employees and no publicly disclosed products, customers, or pricing.

The company is led by a three-person founding team combining scientific, operational, and technical leadership: Hiroki Ando as Founder, CEO, and Chief Scientific Officer (CScO); Kazuyuki Sakamoto as Co-Founder and Chief Operating Officer (COO); and Shun Iwatani as Co-Founder and Chief Technology Officer (CTO). The composition suggests a science-led organization pairing wet-lab research direction (CScO) with platform/technology buildout (CTO) and operational scaling (COO). The company maintains a public web presence at arrowsmith.co.jp.

Arrowsmith has raised approximately $48.3 million across two funding rounds within roughly ten months of incorporation. The Series 1 in August 2025 was $41.8M and led by JIC Venture Growth Investments with JAFCO participating; the Series 2 in June 2026 was approximately $6.5M and broadened the syndicate to include ANRI and DBJ Capital alongside JAFCO and JIC Venture Growth Investments. The business model, revenue mechanics, product pipeline, and go-to-market strategy are not disclosed in the available input data, and represent material information gaps for any commercial assessment.

Short descriptiontext

Arrowsmith is a Japan-based biotech startup founded in 2025 that targets antimicrobial resistance, led by a three-person founder team spanning scientific, operational, and technical functions, and capitalized by approximately $48M in equity funding.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTsukuba, Japan
HQ citystring
Tsukuba
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
antimicrobial resistance, biotechnology research, drug discovery, infectious disease therapeutics, life sciences
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAJAIAF
Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
Product category
Biotechnology / Antimicrobial Drug Discovery
No data
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Arrowsmith is a Japan-based biotechnology company developing solutions aimed at combating antimicrobial resistance (AMR). The company focuses on research and development of therapeutic approaches to address drug-resistant infections, with the stated mission of creating a world free from the pain and fear of antimicrobial resistance.

Differentiator
Functional benefit
Problem solved
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Daiichi Sankyo is one of Japan's largest pharmaceutical companies with research programs in infectious disease and historical involvement in antimicrobial R&D. As a major Japanese incumbent, it represents a relevant comparable for scale, geography, and potential strategic engagement with focused AMR biotechs.

TypeBroad incumbent
Description

Roche is a global pharmaceutical and diagnostics leader with substantial infectious disease and AMR-related diagnostics investments (e.g., cobas systems). It represents a comparable large incumbent whose combined pharma-diagnostics approach frames the strategic universe in which pure-play AMR therapeutics like Arrowsmith operate.

TypeDirect peer
Description

Paratek Pharmaceuticals (now part of Gurnet Point) developed and commercialized antibiotics including omadacycline targeting resistant pathogens. Its end-to-end AMR focus, from discovery through approval, makes it a structurally comparable peer to Arrowsmith.

TypeDirect peer
Description

Cidara Therapeutics develops antiviral and antimicrobial Cloudbreak drug-Fc conjugates targeting serious infections including influenza and AMR-related indications. Its antimicrobial platform and pipeline focus makes it a directly comparable early-stage AMR peer to Arrowsmith.

TypeDirect peer
Description

Melinta Therapeutics is a US antibiotics-focused company developing therapies for drug-resistant bacterial infections, including commercial-stage products like vabomere. It directly parallels Arrowsmith as a pure-play antimicrobial therapeutics developer serving the same AMR market.

TypeBroad incumbent
Description

Shionogi is a major Japanese pharmaceutical company with a leading antimicrobial franchise including the recently launched cefiderocol. As a regional incumbent with deep AMR expertise and Japanese domicile, it represents the most credible local industry anchor Arrowsmith may partner with, acquire assets from, or eventually exit to.

TypeDirect peer
Description

Iterum Therapeutics is a clinical-stage US biotech developing oral and intravenous antibiotics targeting multi-drug resistant pathogens. It is a direct comparable to Arrowsmith given its singular focus on combating AMR through novel antimicrobial chemistry.

TypeBroad incumbent
Description

Pfizer is a global pharmaceutical leader with an active antimicrobial portfolio and a founding role in the AMR Action Fund. As a broad incumbent with explicit strategic commitment to replenishing the antibiotic pipeline, Pfizer is a meaningful benchmark for the corporate development opportunities facing AMR-focused companies like Arrowsmith.

9Meiji Seika Pharma
TypeRegional player
Description

Meiji Seika Pharma is a Japanese pharmaceutical subsidiary of Meiji Holdings with a long-standing antibiotics portfolio including carbapenems. It is comparable to Arrowsmith as a Japan-headquartered company with deep AMR focus and serves as a likely strategic peer or potential acquirer within the domestic market.

TypeDirect peer
Description

VenatoRx Biosciences is a privately-held US biotech developing new antibiotics active against resistant Gram-negative pathogens. Its narrow focus on novel antibacterial chemistry to address AMR directly mirrors Arrowsmith's therapeutic thesis and stage profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arrowsmith

Biotechnology / Antimicrobial Drug Discoveryarrowsmith.co.jp

Arrowsmith is a Japan-based biotech startup founded in 2025 that targets antimicrobial resistance, led by a three-person founder team spanning scientific, operational, and technical functions, and capitalized by approximately $48M in equity funding.

What Arrowsmith does

Arrowsmith Inc. is a Japan-based, privately held biotechnology company founded in 2025 and headquartered in Ibaraki. Its stated mission is to address antimicrobial resistance (AMR), positioning the company in the global effort to develop countermeasures against drug-resistant infections. The company is in an early operational stage, with a headcount reported at 1-10 employees and no publicly disclosed products, customers, or pricing.

The company is led by a three-person founding team combining scientific, operational, and technical leadership: Hiroki Ando as Founder, CEO, and Chief Scientific Officer (CScO); Kazuyuki Sakamoto as Co-Founder and Chief Operating Officer (COO); and Shun Iwatani as Co-Founder and Chief Technology Officer (CTO). The composition suggests a science-led organization pairing wet-lab research direction (CScO) with platform/technology buildout (CTO) and operational scaling (COO). The company maintains a public web presence at arrowsmith.co.jp.

Arrowsmith has raised approximately $48.3 million across two funding rounds within roughly ten months of incorporation. The Series 1 in August 2025 was $41.8M and led by JIC Venture Growth Investments with JAFCO participating; the Series 2 in June 2026 was approximately $6.5M and broadened the syndicate to include ANRI and DBJ Capital alongside JAFCO and JIC Venture Growth Investments. The business model, revenue mechanics, product pipeline, and go-to-market strategy are not disclosed in the available input data, and represent material information gaps for any commercial assessment.

Arrowsmith firmographics

Firmographics
Name
Arrowsmith
Legal name
Arrowsmith Inc.
Website
https://arrowsmith.co.jp
Company type
Private
Founded year
2025
Headcount range
1–10 employees
Short description
Arrowsmith is a Japan-based biotech startup founded in 2025 that targets antimicrobial resistance, led by a three-person founder team spanning scientific, operational, and technical functions, and capitalized by approximately $48M in equity funding.
Ownership category
akta.pro rank

Arrowsmith industry classification

Industry
Product category
Biotechnology / Antimicrobial Drug Discovery
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAJAIAF
Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

  • Antimicrobial resistance
  • Biotechnology research
  • Drug discovery
  • Infectious disease therapeutics
  • Life sciences

Where Arrowsmith is headquartered

Location

Headquarters

HQ city
Tsukuba
HQ country
Japan
HQ region
Asia

Markets served

Arrowsmith business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Arrowsmith product offering

Product offering

Core offering

Arrowsmith is a Japan-based biotechnology company developing solutions aimed at combating antimicrobial resistance (AMR). The company focuses on research and development of therapeutic approaches to address drug-resistant infections, with the stated mission of creating a world free from the pain and fear of antimicrobial resistance.

Differentiator

Problem solved

Functional benefit

Companies that use Arrowsmith

Customer profile

Ideal customer profiles1 record

Arrowsmith technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Arrowsmith partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Arrowsmith competitors and assessment

Company assessment

Broad incumbents

  • Daiichi Sankyo: Daiichi Sankyo is one of Japan's largest pharmaceutical companies with research programs in infectious disease and historical involvement in antimicrobial R&D. As a major Japanese incumbent, it represents a relevant comparable for scale, geography, and potential strategic engagement with focused AMR biotechs.
  • Roche: Roche is a global pharmaceutical and diagnostics leader with substantial infectious disease and AMR-related diagnostics investments (e.g., cobas systems). It represents a comparable large incumbent whose combined pharma-diagnostics approach frames the strategic universe in which pure-play AMR therapeutics like Arrowsmith operate.
  • Shionogi & Co. Shionogi is a major Japanese pharmaceutical company with a leading antimicrobial franchise including the recently launched cefiderocol. As a regional incumbent with deep AMR expertise and Japanese domicile, it represents the most credible local industry anchor Arrowsmith may partner with, acquire assets from, or eventually exit to.
  • Pfizer: Pfizer is a global pharmaceutical leader with an active antimicrobial portfolio and a founding role in the AMR Action Fund. As a broad incumbent with explicit strategic commitment to replenishing the antibiotic pipeline, Pfizer is a meaningful benchmark for the corporate development opportunities facing AMR-focused companies like Arrowsmith.

Direct peers

  • Paratek Pharmaceuticals: Paratek Pharmaceuticals (now part of Gurnet Point) developed and commercialized antibiotics including omadacycline targeting resistant pathogens. Its end-to-end AMR focus, from discovery through approval, makes it a structurally comparable peer to Arrowsmith.
  • Cidara Therapeutics: Cidara Therapeutics develops antiviral and antimicrobial Cloudbreak drug-Fc conjugates targeting serious infections including influenza and AMR-related indications. Its antimicrobial platform and pipeline focus makes it a directly comparable early-stage AMR peer to Arrowsmith.
  • Melinta Therapeutics: Melinta Therapeutics is a US antibiotics-focused company developing therapies for drug-resistant bacterial infections, including commercial-stage products like vabomere. It directly parallels Arrowsmith as a pure-play antimicrobial therapeutics developer serving the same AMR market.
  • Iterum Therapeutics: Iterum Therapeutics is a clinical-stage US biotech developing oral and intravenous antibiotics targeting multi-drug resistant pathogens. It is a direct comparable to Arrowsmith given its singular focus on combating AMR through novel antimicrobial chemistry.
  • VenatoRx Biosciences: VenatoRx Biosciences is a privately-held US biotech developing new antibiotics active against resistant Gram-negative pathogens. Its narrow focus on novel antibacterial chemistry to address AMR directly mirrors Arrowsmith's therapeutic thesis and stage profile.

Regional players

  • Meiji Seika Pharma: Meiji Seika Pharma is a Japanese pharmaceutical subsidiary of Meiji Holdings with a long-standing antibiotics portfolio including carbapenems. It is comparable to Arrowsmith as a Japan-headquartered company with deep AMR focus and serves as a likely strategic peer or potential acquirer within the domestic market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Arrowsmith financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arrowsmith leadership team

Management profile

Number of profiles

Profiles3 records

Arrowsmith funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arrowsmith M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arrowsmith

What does Arrowsmith do?

Arrowsmith is a Japan-based biotechnology company developing solutions aimed at combating antimicrobial resistance (AMR). The company focuses on research and development of therapeutic approaches to address drug-resistant infections, with the stated mission of creating a world free from the pain and fear of antimicrobial resistance.

When was Arrowsmith founded?

Arrowsmith was founded in 2025. It employs 1 to 10 people.

Where is Arrowsmith based?

Arrowsmith is headquartered in Tsukuba, Japan, in the Asia region.

Who are Arrowsmith's main competitors?

Broad incumbents on record are Daiichi Sankyo, Roche, Shionogi & Co. and Pfizer. Direct peers are Paratek Pharmaceuticals, Cidara Therapeutics, Melinta Therapeutics, Iterum Therapeutics and VenatoRx Biosciences. Meiji Seika Pharma is listed as a regional player.

Does Arrowsmith have an API?

No public API is recorded for Arrowsmith.

What industry is Arrowsmith in?

Arrowsmith's product category is Biotechnology / Antimicrobial Drug Discovery. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAJAIAF, Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales